The Global Multiomics Market size is expected to reach $5.7 billion by 2030, rising at a market growth of 15.0% CAGR during the forecast period.
Metabolomics aids is understanding how individuals metabolize drugs, which is critical for precision medicine. Thus, Metabolomics segment acquired $215 million in 2022. It can predict drug responses and identify potential adverse reactions, leading to optimized therapeutic strategies. Therefore, these factors will propel the expansion of the metabolomics segment in the upcoming years. Discovering biomarkers linked to many diseases, such as cancer, cardiovascular disease, diabetes, and neurological problems, has become much easier with metabolomics. The identification of disease-specific metabolites holds promise for early diagnosis and personalized treatment.
The major strategies followed by the market participants are Partnerships, Collaborations & Agreements as the key developmental strategy to keep pace with the changing demands of end users. For instance, In January, 2023, Bruker Corporation partnered with Biognosys AG. Under this partnership, both companies would create unique synergies between Biognosys’ versatile offerings of proprietary proteomics services, software, and kits, and Bruker’s pioneering timsTOF platform. Additionally, In November, 2022, BGI Group signed an agreement with the University of Pécs to launch a joint laboratory in Hungary. Additionally, this world-class facility would hasten the development of genomic sequencing and clinical diagnostic services.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc, Illumina, Inc., Danaher Corporation, PerkinElmer, Inc., Bruker Corporation, Qiagen N.V., Agilent Technologies, Inc., BGI Group, Becton, Dickinson, and Company, Shimadzu Corporation
Metabolomics aids is understanding how individuals metabolize drugs, which is critical for precision medicine. Thus, Metabolomics segment acquired $215 million in 2022. It can predict drug responses and identify potential adverse reactions, leading to optimized therapeutic strategies. Therefore, these factors will propel the expansion of the metabolomics segment in the upcoming years. Discovering biomarkers linked to many diseases, such as cancer, cardiovascular disease, diabetes, and neurological problems, has become much easier with metabolomics. The identification of disease-specific metabolites holds promise for early diagnosis and personalized treatment.
The major strategies followed by the market participants are Partnerships, Collaborations & Agreements as the key developmental strategy to keep pace with the changing demands of end users. For instance, In January, 2023, Bruker Corporation partnered with Biognosys AG. Under this partnership, both companies would create unique synergies between Biognosys’ versatile offerings of proprietary proteomics services, software, and kits, and Bruker’s pioneering timsTOF platform. Additionally, In November, 2022, BGI Group signed an agreement with the University of Pécs to launch a joint laboratory in Hungary. Additionally, this world-class facility would hasten the development of genomic sequencing and clinical diagnostic services.
Cardinal Matrix
Market Competition Analysis
Based on the Analysis presented in the Cardinal Matrix; Danaher Corporation and Thermo Fisher Scientific, Inc. are the forerunners in the Market. Companies such as Bruker Corporation, Illumina, Inc. and Becton Dickinson and Company are some of the key innovators in the Market. In January, 2022, Illumina, Inc. partnered with SomaLogic, a protein biomarker discovery and clinical diagnostics company. This partnership aimed to hasten the rapidly growing high throughput sector of the proteomics market.
Market Growth Factors
Rising advancements in high-throughput omics technologies
High-throughput omics technologies have substantially reduced the cost of data generation. This cost-effectiveness has democratized access to multiomics research, making it more affordable for a wider range of researchers, institutions, and companies. As a result, more players are entering the market, fostering innovation and competition. This level of granularity is critical for identifying potential biomarkers and therapeutic targets. The lowered barriers to entry have fostered a thriving ecosystem of start-ups and companies specializing in omics technologies and services. These factors are expected to boost the demand in the future.Growing demand for personalized medicines worldwide
The emphasis on personalized medicine encourages healthcare providers and researchers to utilize multiomics technologies to a greater extent. This includes genomics, transcriptomics, proteomics, and metabolomics, which provide comprehensive insights into an individual's molecular and genetic makeup. This increased utilization leads to greater demand for multiomics services and solutions. Multiomics data can provide a detailed understanding of a patient's genetic predispositions, biomarker profiles, and disease risks. This integration boosts the demand for multiomics technologies and services. The demand for these data in personalized medicine has created opportunities for innovative start-ups and established companies to provide specialized services and technologies. Thus, these factors will drive the expansion of the market in the upcoming years.Market Restraining Factors
Continually evolving regulatory environment of multiomics
Data sharing is vital for scientific collaboration and the advancement of multiomics research. However, the need to protect patient privacy and comply with regulations can limit the extent to which data can be shared. This may hinder collaborative research efforts and restrict the availability of multiomics datasets. Regulatory changes can be frequent and unpredictable. Organizations in this market must continuously monitor and adapt to evolving regulations, which can introduce uncertainty into their operations. Regulatory shifts can necessitate changes in data handling, research methodologies, and business models. These factors are expected to limit the growth of this market in the coming years.Type Outlook
On the basis of type, the market is divided into single-cell multiomics and bulk multiomics. The bulk multiomics segment recorded the maximum revenue share in the market in 2022. The availability of sophisticated bioinformatics tools and data integration platforms has facilitated the analysis and interpretation of bulk multiomics data. Researchers can now perform cross-omics analyses with relative ease, identifying correlations and patterns across different data types. Bulk multiomics plays a pivotal role in the advancement of precision medicine. By analyzing an individual's multiomics profile, clinicians can tailor treatments to their unique molecular characteristics. This approach holds significant promise for improving patient outcomes and reducing adverse effects. Owing to these factors, there will be an increased demand in the bulk multiomics segment.Product & Service Outlook
Based on product & service, the market is segmented into products and services. In 2022, the services segment garnered a significant revenue share in the market. The continued development of high-throughput omics technologies has made generating vast amounts of data possible. However, analyzing this data requires specialized expertise, leading to a greater reliance on services offered by dedicated providers. Multiomics data is inherently complex, with a multitude of variables and interactions. The interpretation of this data demands sophisticated bioinformatics and computational tools, creating a niche for service providers to offer data analysis and interpretation solutions. These factors are expected to propel the demand in the services segment.Product Outlook
The product segment is further subdivided into instruments, consumables, and software. In 2022, the instruments subsegment procured the highest revenue share in the market. Next-generation sequencing (NGS) platforms have witnessed remarkable advancements in sequencing capacity, read length, and data quality. These improvements have led to increased adoption of NGS for genomics and transcriptomics studies. Mass spectrometry technology has become more sensitive and capable of analyzing a broader range of molecules. This has expanded its use in proteomics and metabolomics research.End-use Outlook
On the basis of end-use, the market is divided into academic & research institutes, pharmaceutical & biotechnology companies, and others. The academic and research institutes segment recorded the maximum revenue share in the market in 2022. Academic and research institutes have benefited from the growing availability of research funding from government sources and private foundations. Funding agencies recognize the importance of multiomics research in advancing scientific knowledge and addressing complex health and environmental challenges. This increased funding has allowed academic and research institutions to expand their multiomics research initiatives.
Platform Outlook
Based on platform, the market is segmented into genomics, transcriptomics, proteomics, metabolomics, and integrated omics platforms. The proteomics segment procured a promising growth rate in the market in 2022. Proteomic platforms can determine the functions of proteins, which is crucial for understanding their roles in various biological processes. This information is valuable for basic research and applied sciences. Proteomic analysis can also help in identifying proteins that can serve as therapeutic targets. In industries such as biopharmaceuticals, proteomic platforms are used for quality control to ensure the consistency and safety of products.Application Outlook
On the basis of application, the market is divided into cell biology, oncology, neurology, and immunology. The cell biology segment recorded the maximum revenue share in the multiomics market in 2022. Cell biology, in conjunction with multiomics, plays a crucial role in cancer research and precision oncology. Researchers can now profile the molecular alterations in cancer cells in unprecedented detail. This has led to the discovery of new drug targets, the development of targeted therapies, and the identification of resistance mechanisms. It also contributes to personalizing cancer treatment regimens, improving patient outcomes. Owing to these factors, the demand will rise in the segment.Regional Outlook
By region, the market is segmented into North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the market in 2022. North America boasts a robust and well-funded research ecosystem with leading universities, academic institutions, and research organizations at the forefront of multiomics studies. These institutions have been driving research, publishing groundbreaking findings, and attracting substantial research funding. Thus, there will be increased demand in the segment.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc, Illumina, Inc., Danaher Corporation, PerkinElmer, Inc., Bruker Corporation, Qiagen N.V., Agilent Technologies, Inc., BGI Group, Becton, Dickinson, and Company, Shimadzu Corporation
Strategies deployed in the Market
Partnerships, Collaborations, and Agreements:
- Mar-2023: Illumina Inc. came into partnership with Myriad Genetics Inc., a leader in genetic testing and precision medicine. This partnership aimed to widen access to and availability of oncology homologous recombination deficiency testing in the United States.
- Jan-2023: Bruker Corporation partnered with Biognosys AG, a Switzerland-based company. Under this partnership, both companies would create unique synergies between Biognosys’ versatile offerings of proprietary proteomics services, software, and kits, and Bruker’s pioneering timsTOF platform.
- Nov-2022: BGI Group signed an agreement with the University of Pécs, the largest higher education institution in Hungary. This agreement aimed to launch a joint laboratory in Hungary. Additionally, this world-class facility would hasten the development of genomic sequencing and clinical diagnostic services, while empowering BGI Genomics and the UP's leadership in genomics, bioinformatics, reproductive health, and precision medicine in the Central and Eastern European region.
- Oct-2022: Illumina Inc. collaborated with AstraZeneca, a global, science-led biopharmaceutical company. This collaboration aimed to hasten drug target discovery by integrating strengths in artificial intelligence-based genome interpretation and genomic analysis techniques along with industry expertise. Additionally, this collaboration would evaluate whether a combined framework of these technologies could increase the yield and confidence of target discovery to find promising drugs based on human omics insights.
- Feb-2022: Agilent Technologies Inc. came into partnership with MRM Proteomics, Inc., a biotechnology company. This partnership would offer a complete solution for quantitative protein and metabolite analysis.
- Jan-2022: Illumina, Inc. partnered with SomaLogic, a protein biomarker discovery and clinical diagnostics company. This partnership aimed to hasten the rapidly growing high throughput sector of the proteomics market.
- Jan-2022: Illumina, Inc. signed an agreement with Nashville Biosciences, LLC, a wholly owned subsidiary of Vanderbilt University Medical Center. This agreement aimed to hasten medicines development through large-scale genomics and the establishment of a preeminent clinico-genomic resource.
- Jun-2021: BGI Group collaborated with Champions Oncology, a leading global oncology data-driven solutions provider. This collaboration aimed to provide mass spectrometry-based proteomics and multiomics data analysis solutions.
Product Launches and Product Expansions:
- Sep-2023: Bruker Corporation introduced 4D-Proteomics, MALDI HiPLEX-IHC spatial tissue proteomics, 4D-Lipidomics and 4D-Metabolomics. The launched product would perform precise quantification of peptides and proteins present in 100s or 1000s samples by utilizing global retention time and collision cross-section prediction models.
- Mar-2023: Illumina Inc. released the novel Illumina Complete Long Read technology, a high-performance, long-read, human whole-genome sequencing assay. The launched product would provide users access to both long
- and short-read data on the same Illumina instrument.
- Feb-2023: Becton Dickinson and Company reveiled BD Rhapsody HT Xpress System, a new instrument for single-cell multiomics analysis. This product would allow scientists to run high-throughput studies without sacrificing sample integrity potentially accelerating time to discovery across a broad range of disciplines including immunology, genetic disease research, and cancer and chronic disease research.
- Jun-2022: Bruker Corporation rolled out the timsTOF HT system, a novel 4th-generation TIMS XR cell and 14-bit digitizer for an even greater dynamic range. The launched product would improve peptide coverage and more accurate quantitation, especially in unbiased 4D plasma and tissue proteomics and epiproteomics.
Acquisition and Mergers:
- Jan-2022: Bruker Corporation acquired Prolab Instruments GmbH, a Swiss technology company. This acquisition aimed to Augment Multiomics Solutions.
- Aug-2021: Illumina, Inc. took over GRAIL, a healthcare company focused on life-saving early detection of multiple cancers. This acquisition aimed to accelerate access and adoption of this life-saving test globally.
- Sep-2020: Bruker Corporation took over Canopy Biosciences LLC, a company specializing in high multiplex biomarker imaging for immunology, immuno-oncology, and cell therapy. This acquisition aimed to improve Bruker’s portfolios in targeted multi-omics and fluorescence-based imaging techniques.
Geographical Expansions:
- Aug-2023: Illumina Inc. opened a new facility Illumina Solutions Center in Bengaluru, India. The new facility would support Illumina Inc. to grow the genomics market in India.
Scope of the Study
Market Segments Covered in the Report:
By Type- Bulk Multiomics
- Single-cell Multiomics
- Product
- Instruments
- Consumables
- Software
- Services
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics
- Integrated Omics Platforms
- Cell Biology
- Oncology
- Neurology
- Immunology
- North America
- US
- Canada
- Mexico
- Rest of North America- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc
- Illumina, Inc.
- Danaher Corporation
- PerkinElmer, Inc.
- Bruker Corporation
- Qiagen N.V.
- Agilent Technologies, Inc.
- BGI Group
- Becton, Dickinson, and Company
- Shimadzu Corporation
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Global Multiomics Market by Type
Chapter 6. Global Multiomics Market by Product & Service
Chapter 7. Global Multiomics Market by End-use
Chapter 8. Global Multiomics Market by Platform
Chapter 9. Global Multiomics Market by Application
Chapter 10. Global Multiomics Market by Region
Chapter 11. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific, Inc
- Illumina, Inc.
- Danaher Corporation
- PerkinElmer, Inc.
- Bruker Corporation
- Qiagen N.V.
- Agilent Technologies, Inc.
- BGI Group
- Becton, Dickinson, and Company
- Shimadzu Corporation
Methodology
LOADING...
